The Medicines and Healthcare products Regulatory Agency (MHRA) has published its 2030 Strategy, setting out ambitious plans to translate scientific and technological innovation into better health outcomes. The regulator says that the commitments will enable it to keep pace with rapid advances in science, technology and personalised… Read More
Roche and Zealand Pharma have shared positive topline results from the Phase II ZUPREME-2 trial evaluating petrelintide versus placebo in people living with overweight or obesity and type 2 diabetes. The trial met its primary endpoint, demonstrating that once-weekly subcutaneous injections of petrelintide (escalated every fourth week)… Read More
CSL and Alentis Therapeutics have entered into an exclusive global collaboration agreement to co-develop and co-promote lixudebart, which has the potential to become a first-in-class therapy targeting claudin-1 across a range of kidney, liver and other diseases. Under the terms of the agreement, Alentis will receive a… Read More
Ahead of the Budget, UK life sciences groups have called on the Chancellor to prioritise investment in new medicines. The UK government has set out bold targets for the UK’s life sciences sector. By 2030, it wants the UK to lead Europe in commercial research and development… Read More
Roswell Park Comprehensive Cancer Center and Generate Biomedicines have dosed the first patient in a first-in-human clinical trial evaluating GB-5267, an autologous IL‑18–armoured CAR T-cell therapy. The therapy is designed to overcome key barriers that have limited the success of cellular therapies in solid tumours. … Read More
Kevan Shokat has been named the 2026 Stephenson Global Prize Laureate, receiving $1 million for his pioneering contributions to pancreatic cancer research. His discoveries helped transform decades of scientific thinking about KRAS, one of cancer’s most important and historically difficult-to-target drivers, and usher in a new generation… Read More
Novartis has revealed plans to pause development of Lifonebart (VHB937), an experimental monoclonal antibody drug targeting the TREM2 protein to treat neurodegenerative diseases. The news comes just days after the company announced its Phase III trial of antibody oligonucleotide conjugate (AOC) del-desiran had failed. VHB937… Read More
US researchers have filed a class action lawsuit challenging the National Institutes of Health’s (NIH) policy of blocking grants to censor views it disagrees with, on everything from DEI to gender identity to climate change. The plaintiffs are represented by the American Civil Liberties Union, the ACLU… Read More
Johnson & Johnson has announced final overall survival (OS) results from the Phase III PAPILLON study of first-line intravenous (IV) Rybrevant (amivantamab). The fully-human EGFR-MET bispecific antibody was assessed with carboplatin-pemetrexed chemotherapy, versus chemotherapy alone, in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth… Read More
Novartis and Bristol Myers Squibb (BMS) have both paused clinical trials of CAR-T cell therapies for lupus and other autoimmune diseases due to concerning safety findings. Novartis has placed holds on trials of rapcabtagene autoleucel (rap-cel), stopping screening, randomisation, and treatment administration in trials in lupus, myasthenia… Read More
Eli Lilly has announced plans to acquire Merida Biosciences, a biotechnology company advancing a new class of precision therapeutics for serious autoimmune and allergic diseases. Merida is developing biologics engineered to selectively degrade pathogenic autoantibodies, the disease-causing agents behind a range of immune-mediated conditions. The… Read More
African biopharmaceutical company Minapharm Group will receive up to $16.5 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a Bundibugyo ebolavirus vaccine candidate. The investment is part of efforts to develop vaccines to combat the fastest-growing and second-largest Ebola outbreak on… Read More
Researchers have identified inflammatory cytokine interleukin-26 (IL-26) as a factor that acts on cancer cells and induces epigenetic reprogramming, promoting immune evasion. While cancer cells acquire malignant traits through epigenetic remodelling, it remains unclear how immune-derived inflammatory factors regulate the epigenetics of colorectal cancer cells. … Read More
The world-first trial of a fridge-free tetanus-diphtheria vaccine has produced encouraging results that could improve access worldwide to crucial treatments. Around half of vaccines are wasted globally each year, according to the World Health Organization, because of temperature changes during storage and transport. Fridge-free vaccines… Read More
Following Health Canada’s authorisation, the first participants have been vaccinated in Moderna’s Phase I clinical study evaluating mRNA-1469, an mRNA vaccine to prevent Bundibugyo ebolavirus (BDBV). “Vaccinating the first participants with mRNA-1469 marks an important milestone in advancing a vaccine candidate against Bundibugyo ebolavirus, for which no… Read More
Norstella has announced the launch of the Pipeline-to-Patient Productivity Index (P3i), a new annual benchmark measuring R&D productivity, market access, and commercial return across the top 25 global biopharma companies. The P3i is the first benchmark to follow drug performance across the entire development and commercialisation lifecycle. Read More
